Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Muñoz-Martínez, Sergio; Sapena, Víctor; Forner, Alejandro; Nault, Jean–Charles; Sapisochín, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi‐Zamparelli, Marco; Hołówko, Wacław; Kassas, Mohamed El; Mocan, Tudor; Benameur, M.; Merle, Philippe; Hoogwater, Frederik J.H.; Alqahtani, Saleh A.; Reeves, Helen L.; Pinato, David J.; Giorgakis, Emmanouil; Meyer, Tim; Villadsen, Gerda Elisabeth; Wege, Henning; Salati, Massimiliano; Mínguez, Beatriz; Costanzo, Giovan Giuseppe Di; Roderburg, Christoph; Tacke, Frank; Varela, Marı́a; Galle, Peter R.; Álvares‐da‐Silva, Mário Reis; Trojan, Jörg; Bridgewater, John; Cabibbo, Giuseppe; Toso, Christian; Lachenmayer, Anja; Casadei-Gardini, Andrea; Toyoda, Hidenori; Lüdde, Tom; Villani, Rosanna; Peña, Ana María Matilla; Leal, Cassia Regina Guedes; Ronzoni, Monica; Delgado, M. García; Perelló, Christie; Pascual, Sonia; Lledó, José Luis; Argemí, Josepmaria; Basu, Bristi; Fonseca, Leonardo da; Acevedo, Juan; Siebenhüner, Alexander; Braconi, Chiara; Meyers, Brandon M.; Granito, Alessandro; Sala, María; Rodríguez-Lope, Carlos; Blaise, Lorraine; Romero‐Gómez, Manuel; Piñero, Federico; Gomez, Dhanny; Mello, Vivianne; Alves, Rogério Camargo Pinheiro; França, Alex Vianey Callado; Branco, Fernanda; Brandi, Giovanni; Pereira, Gustavo; Coll, Susanna; Guarino, Maria; Benítez, Carlos; Anders, Maria Margarita; Bandi, Juan Carlos; Vergara, Mercedes; Calvo, Mariona; Peck‐Radosavljevic, Markus; García‐Juárez, Ignacio; Cardinale, Vincenzo; Lozano, Mar; Gambato, Martina; Okolicsanyi, S.; Morales-Arráez, Dalia; Elvevi, Alessandra; Muñoz, Alberto; Lué, Alberto; Iavarone, M.; Reig, María

doi:10.1016/j.jhepr.2021.100260

Cited by 40 publications

(56 citation statements)

References 21 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this study are consistent with findings outside of the Asia-Pacific. A multicountry survey 11 focusing on the impact of COVID-19 on HCC management in non-Asian countries found that 87% of centers modified their clinical practices during the pandemic - 41% of centers modified diagnostic procedures, 81% deferred screening programs, and 50% canceled curative and/or palliative treatments. There was also a report of a surge in telephonic consultations in the majority of the centers.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, an international survey assessing the impact of the COVID-19 on liver cancer management also included just one center from Asia (Japan). 11 Since most HCC cases are in Asia-Pacific, a multicountry study from the Asia-Pacific region will be needed to understand the overall impact of the pandemic and inter-country differences. This study was conducted during the initial phase of the pandemic and adopted a multicountry approach.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study

Gandhi¹,

Ling²,

Chen³

et al. 2021

JHC

View full text Add to dashboard Cite

Purpose The COVID-19 pandemic has altered healthcare priorities which may adversely impact cancer management. We aimed to evaluate the impact of the pandemic on the diagnosis, treatment, and consultation methods for patients with hepatocellular carcinoma (HCC). Patients and Methods We conducted a survey among 27 hospitals from 14 Asia-Pacific countries, collecting hospital-level information on the number of newly diagnosed HCC cases during a pre-pandemic period (February to May 2019) and for the same period during the pandemic (February to May 2020). Information was also collected on delays in diagnosis and treatment, changes in treatment modalities and complication rates, changes in patient enrollment in clinical trials, and modes of patient consultation. The information was stratified by the Barcelona Clinic Liver Cancer (BCLC) stage. Results The survey included cohorts of 2789 and 2045 patients newly diagnosed with HCC during the pre- and pandemic period, respectively. A decline of 26.7% in new HCC cases was reported during the pandemic compared to the pre-pandemic. A sizable proportion of institutions reported delays in diagnosis (48.2% in BCLC 0/A/B and 51.9% in BCLC C), delays in treatment (66.7% in BCLC 0/A/B and 63.0% in BCLC C), changes in treatment modality (33.3% in BCLC 0/A/B and 18.5% in BCLC C), an increase in treatment complications (about 15% across all BCLC stages), and no growth in clinical trial enrollments during the pandemic. Furthermore, there was a decline of 27.3% in face-to-face patient consultations and an increase of 18.3% in video/telephonic consultations during the pandemic. A considerable variation in changes in HCC management was observed among countries. Conclusion The COVID-19 pandemic has significantly impacted the management of HCC among Asia-Pacific countries. The impact varies according to the disease stage and country. Well thought-through long-term strategies are required to ameliorate the negative impact of the pandemic on HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study

Gandhi¹,

Ling²,

Chen³

et al. 2021

JHC

View full text Add to dashboard Cite

show abstract

“…This active involvement of the Oncology nurse should be further developed together with optimal criteria for telephonic/video consultations. 96…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

COVID‐19 and the liver: A 2021 update

Spearman

Aghemo

Valenti

et al. 2021

Liver International

View full text Add to dashboard Cite

a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. 1 Its genomic sequence is 79.6% homologous with human SARS-CoV and is responsible for the now-known coronavirus disease 2019 or COVID-19. 2 Globally, to date, excess of 165 million people have been infected with 3.4 million attributable deaths, and the incidence continues to increase. 3 COVID-19 is primarily a respiratory illness that may be complicated by pneumonia and acute respiratory distress syndrome (ARDS). However, the disease has also several extra-pulmonary manifestations involving the haematological, cardiovascular, renal, gastrointestinal and hepatobiliary, endocrine, neurological, ophthalmological and dermatological systems. 4 Here, we shortly review the pathophysiology of COVID-19, with a special focus on the

show abstract

“…COVID-19 pandemic has caused significant delay in the diagnosis and treatment of various gastrointestinal cancers [22][23][24][25][26][27]. The decline in number of surgeries in 2020 has been due to multiple factors including delayed diagnosis due to national lockdowns, hesitance of patients to visit hospital, cancelation of endoscopic activity and other cancer screening programs, and cancelations/postponement of elective surgeries due to shortage of hospital resources [25,27,28]. A study from United Kingdom (UK) reported that all nonemergent endoscopies were stopped for 6 weeks in March and April 2020 due to COVID-19 pandemic leading to significant reductions in diagnostic endoscopies and decreased the number of new cancer cases from 677 per week in the pre-COVID period to 283 per week in the COVID times [28].…”

Section: Impact Of Covid-19 Pandemic On Gastrointestinal Surgical Servicesmentioning

confidence: 99%

“…According to a study by Sud et al, delay in cancer surgery by more than 3 months and 6 months may lead to > 17% and > 30% reduction in the survival of patients with stage 2 or 3 gastrointestinal cancers [26]. An international survey involving 76 centers across the world found that 50% curative and/or palliative treatments for liver cancer and 44% liver transplants were canceled during COVID-19 pandemic from March to June 2020 [25].…”

Section: Impact Of Covid-19 Pandemic On Gastrointestinal Surgical Servicesmentioning

confidence: 99%

Impact of COVID-19 on the outcomes of gastrointestinal surgery

Gupta

Ammar

2021

Clin J Gastroenterol

View full text Add to dashboard Cite

COVID-19 pandemic has brought a paradigm shift in the treatment of various surgical gastrointestinal disorders. Given the increasing number of patients requiring hospitalization and intensive care for SARS-CoV-2 infections, various surgical departments worldwide were forced to stop or postpone elective surgeries to save the health resources for COVID-19 patients. Since the declaration of the COVID-19 pandemic by the World Health Organization on 12th March 2020, the recommendations from the surgical societies kept evolving to help the surgeons in making informed decisions regarding patient care. Moreover, various socio-economic and epidemiological factors have come into play while deciding the optimal approach towards patients requiring gastrointestinal surgery. Surgeries for many abdominal diseases such as acute appendicitis and acute calculous cholecystitis were postponed. Elective surgeries were triaged based on the urgency of performing the surgical procedure, the hospital burden of COVID-19 patients, and the availability of healthcare resources. Various measures were adopted such as preoperative screening for SARS-CoV-2 infection, use of personal protective equipment, and the COVID-19-free surgical pathway to prevent perioperative SARS-CoV-2 transmission. In this article, we have reviewed the recent studies reporting the outcomes of various gastrointestinal surgeries in the COVID-19 pandemic era and the recommendations from various surgical societies on the safety precautions to be followed during gastrointestinal surgery.

show abstract

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Cited by 40 publications

References 21 publications

Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study

Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study

COVID‐19 and the liver: A 2021 update

Impact of COVID-19 on the outcomes of gastrointestinal surgery

Contact Info

Product

Resources

About